Showing 4481-4490 of 8828 results for "".
- One Year Data: Cutera’s AviClear Continues to Improve Acnehttps://practicaldermatology.com/news/one-year-data-cuteras-aviclear-comtinues-to-improves-acne/2461400/Cutera, Inc.’s AviClear improves acne in 92 percent of patients at one year, according to research presented at the Annual Fall Clinical Dermatology Conference in Las Vegas. Current clinical studies show that after three 30-minute treatment sessions, 90 percent of patients had a v
- Nivolumab Shows Promise in Advanced SCChttps://practicaldermatology.com/news/nivolumab-shows-promise-in-advanced-scc/2461399/Numerous studies have shown that immune checkpoint inhibitors can boost the immune system’s response against various cancers, and now, a phase II clinical trial has demonstrated that patients with advanced cutaneous squamous cell carcinoma can benefit from nivolumab. The research is publish
- Hair Straightening Chemicals Associated with Higher Uterine Cancer Riskhttps://practicaldermatology.com/news/hair-straightening-chemicals-associated-with-higher-uterine-cancer-risk/2461397/Chemical hair straighteners may be contributing to a rise in aggressive uterine cancers a new study in the Journal of the National Cancer Institute suggests. The
- European Commission Approves LEO Pharma’s Adtralza (tralokinumab) for the Treatment of Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/european-commission-approves-leo-pharmas-adtralza-tralokinumab-for-the-treatment-of-moderate-to-severe-ad-in-adolescents/2461394/The European Commission (EC)e xtended the marketing authorization for LEO Pharma’s Adtralz (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. “Safety is a priority when s
- Aesthetics Biomedical's Vivace Ultra Wins FDA Clearancehttps://practicaldermatology.com/news/aesthetics-biomedicals-vivace-ultra/2461390/The FDA has given the nod to Aesthetics Biomedical Inc.’s Vivace Ultra for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. An innovative reimagination and technical upgrade of the legacy Vivace Microneedle RF device, the Vivace Ultra comb
- Study: Psoriasis Does Not Appear to Increase Heart Attack Risk in People with Significant Kidney Diseasehttps://practicaldermatology.com/news/study-psoriasis-does-not-appear-to-increase-heart-attack-risk-in-people-with-significant-kidney-disease/2461387/Studies have suggested that psoriasis is an independent risk factor for heart attack in the general population, but investigators recently found that in people who also have end-stage renal disease, which shares many risk factors with heart disease, it is not. “There are a lot of
- Galderma's Alastin Rolls Out Pigment-Reducing A-LUMINATE BRIGHTENING SERUMhttps://practicaldermatology.com/news/galdermas-alastin-rolls-out-pigment-reducing-a-luminate-brightening-serum/2461386/Galderma’s ALASTIN Skincare is rolling out A-LUMINATE BRIGHTENING SERUM to help reduce the appearance of surface pigmentation without any harsh, irritating ingredients. A-LUMINATE BRIGHTENING SERUM contains a multifaceted blend of peptides, antioxidants, and targeted in
- ASDSA's 2022 Top Advocates Recognizedhttps://practicaldermatology.com/news/asdsas-2022-top-advocates-recognized/2461381/Meet the American Society for Dermatologic Surgery Association (ASDSA) honorees from the fourth annual Top Advocate program Honorees are chosen based on their contribution to various advocacy efforts throughout the year and demonstrated commitment to patient safety in the field of derma
- ASDSA Names 2022 Patient Safety Hero Awardeeshttps://practicaldermatology.com/news/asdsa-names-2022-patient-safety-hero-awardees/2461379/Mathew Avram, MD, JD and Joel Cohen, MD received the
- Octagam 10% Performs Well in Adults with Dermatomyositishttps://practicaldermatology.com/news/octagam-10-performs-well-in-adults-with-dermatomyositis/2461376/Octapharma’s Octagam 10% [Immune Globulin Intravenous (Human)] is efficacious and well-tolerated in adults with dermatomyositis, ac